No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ATXS240517P7500
- 0.12
- 0.000.00%
15min DelayTrading May 2 12:18 ET
0.00High0.00Low
0.00Open0.12Pre Close0 Volume26 Open Interest7.50Strike Price0.00Turnover266.88%IV-24.15%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.12Time Value100Contract SizeAmericanOptions Type-0.1047Delta0.0834Gamma81.08Leverage Ratio-0.0720Theta-0.0001Rho-8.49Eff Leverage0.0015Vega
Intraday
- 5D
- 1D
News
Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Express News | Wedbush Reiterates Outperform on Astria Therapeutics, Maintains $22 Price Target
Astria TherapeuticS GAAP EPS of -$0.38 Misses by $0.02
Express News | Astria Therapeutics Q1 2024 GAAP EPS $(0.38), Inline
Astria Therapeutics Appointed Sunil Agarwal to Its Bd >ATXS
Astria Therapeutics Appointed Sunil Agarwal to Its Bd >ATXS
Astria Therapeutics 1Q Loss/Shr 38c >ATXS
Astria Therapeutics 1Q Loss/Shr 38c >ATXS
Comments
$Astria Therapeutics Inc(ATXS.US$ Astria Therapeutics Enters Worldwide Exclusive License Agreement With Ichnos Sciences For An OX40 Portfolio; To Pay Ichnos One-time Upfront License Fee Of $15M, Up To $305M In Milestones
Moomoo 24/7· 17 mins ago![]()
Moomoo 24/7· 17 mins ago
1
Read more
TrytosaveabitOP : Going on my watch list